Trevi Therapeutics stock (US89357P1049): clinical data and funding plans move biotech into focus

Trevi Therapeutics is drawing attention after presenting new Haduvio data in chronic cough and outlining fresh financing steps. What drives the story behind the Nasdaq-listed biotech — and what US investors should know about its pipeline and cash runway.

Trevi Therapeutics stock is back on the radar of biotech investors after the company reported new clinical data for its lead drug candidate Haduvio in chronic cough and provided updates on its funding strategy in recent regulatory filings, according to Trevi investor update as of 05/2026 and Nasdaq data as of 05/2026.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Trevi Therapeutics
• Sector/industry: Biopharmaceuticals, specialty neurology/respiratory
• Headquarters/country: New Haven, Connecticut, USA
• Core markets: United States and Europe (clinical development with future commercial focus on US)
• Key revenue drivers: Potential future sales of Haduvio if approved for chronic cough and other refractory pruritic conditions
• Home exchange/listing venue: Nasdaq Capital Market (ticker: TRVI)
• Trading currency: USD

Trevi Therapeutics: core business model

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio, an oral extended-release formulation of nalbuphine designed to act on opioid receptors in the central nervous system for conditions involving chronic coughing and severe itching. The company does not yet generate product revenue and currently finances operations through equity offerings and collaborations, according to Trevi Form 10-Q as of 03/2026.

The core business model revolves around advancing Haduvio through late-stage clinical trials in areas with significant unmet need, such as chronic pruritic conditions and refractory chronic cough, in order to eventually secure regulatory approvals in the United States and other major markets. Management emphasizes targeted indications where current treatment options are limited or poorly tolerated, seeking a potential competitive edge with Haduvio’s mechanism of action, as outlined in the company’s latest corporate presentation and filings, according to Trevi corporate presentation as of 04/2026.

As a Nasdaq-listed micro-cap, Trevi Therapeutics must balance ambitious clinical plans with disciplined cash management. The company reported a net loss and negative operating cash flow for recent quarters as it continues to invest heavily in clinical development and regulatory preparation activities. This pattern is typical for clinical-stage biotechs that have not yet transitioned to commercial sales, but it increases dependency on the capital markets and supportive investor sentiment, as summarized in recent earnings materials from the company and third-party market data providers, according to MarketBeat earnings overview as of 05/2026.

Main revenue and product drivers for Trevi Therapeutics

The central potential revenue driver for Trevi Therapeutics is Haduvio, which is being studied for chronic cough associated with idiopathic pulmonary fibrosis and for pruritic conditions such as chronic itch. These indications represent markets where patients often cycle through multiple therapies without satisfactory relief, providing room for treatments with differentiated efficacy and tolerability profiles, according to Invezz company profile as of 05/2026.

Trevi recently highlighted additional Phase 2b data in chronic cough, reporting a reduction in cough frequency and improvements in patient-reported outcomes compared with baseline in its clinical study. While the trial was not yet a registrational program, management views the results as supportive of moving Haduvio into later-stage development, which would be required before any regulatory submission in the United States. These data underpin the company’s narrative that chronic cough could become a primary commercial opportunity if subsequent studies confirm safety and efficacy, according to Trevi press release as of 04/2026.

In addition to chronic cough, Trevi continues to explore Haduvio in pruritic indications, where severe chronic itching can significantly impair quality of life and sleep. By targeting central nervous system pathways rather than acting purely at the skin level, Haduvio could potentially provide relief in patients who have not responded adequately to topical or systemic therapies. However, these additional uses remain in clinical development and any future revenue contribution would depend on further successful trial results and regulatory clearance in the US and other markets, as described in regulatory filings and investor presentations, according to Trevi annual report as of 03/2026.

Why Trevi Therapeutics matters for US investors

Trevi Therapeutics is listed on the Nasdaq Capital Market under the ticker TRVI, making it directly accessible for US retail and institutional investors who focus on emerging biopharmaceutical companies. The firm’s headquarters in New Haven, Connecticut places it within a well-established ecosystem of academic and clinical research institutions, which can support recruitment for trials and collaborations, according to Nasdaq company overview as of 05/2026.

Exposure to the US healthcare system is central to Trevi’s strategy, as the United States represents one of the largest markets worldwide for innovative treatments that address chronic respiratory and dermatologic symptoms. Pricing and reimbursement frameworks for novel therapies can offer attractive revenue potential, but they also require robust clinical data and negotiation with payers. For investors, the company therefore combines high optionality from potential approvals with the typical risks of clinical setbacks, competition, and reimbursement uncertainty.

Additionally, Trevi shares are included among the holdings of specialized life sciences funds such as the F/M Emerald Life Sciences Innovation ETF, which reflects interest from thematic investors in the company’s pipeline. Such inclusion does not guarantee performance but can support liquidity and visibility among sector-focused investors, according to StockAnalysis ETF holdings overview as of 05/2026.

Conclusion

Trevi Therapeutics is a small US biotech with a focused pipeline built around Haduvio, targeting chronic cough and severe pruritic conditions where current therapies often fall short. Recent Phase 2b data have strengthened management’s case for moving into later-stage trials, but the company continues to post losses and relies on capital markets for funding, according to its latest filings and earnings summaries. For US-focused investors, the stock offers exposure to potential upside from successful development and future commercialization in large addressable markets, balanced by the familiar clinical, regulatory and financing risks that characterize early-stage biopharmaceutical investments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.